MX2020008570A - Inhibidores de arginasa y sus metodos de uso. - Google Patents

Inhibidores de arginasa y sus metodos de uso.

Info

Publication number
MX2020008570A
MX2020008570A MX2020008570A MX2020008570A MX2020008570A MX 2020008570 A MX2020008570 A MX 2020008570A MX 2020008570 A MX2020008570 A MX 2020008570A MX 2020008570 A MX2020008570 A MX 2020008570A MX 2020008570 A MX2020008570 A MX 2020008570A
Authority
MX
Mexico
Prior art keywords
sup
sub
methods
nhr
compounds
Prior art date
Application number
MX2020008570A
Other languages
English (en)
Inventor
Iain Simpson
Maurice Raymond Verschoyle Finlay
Sameer Kawatkar
Dedong Wu
Scott Nathan Mlynarski
Tyler Grebe
Jianyan Wang
Steve Cook
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2020008570A publication Critical patent/MX2020008570A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan compuestos de fórmula (Ia) o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que comprenden compuestos de fórmula (Ia) y métodos para utilizarlas en el tratamiento del cáncer o una enfermedad respiratoria inflamatoria y la inhibición de la arginasa: (ver fórmula) donde R1 es -NHR1a; R1a es -H o -C(O)CH(R1b)NHR1c; y R1b se selecciona entre -H, -alquilo (C1-C4) y CH2OR1d y R1c es -H; o R1b y R1c, junto con el átomo al que están unidos, forman un anillo heterocíclico de 5 miembros; y R1d es H o -CH3;.
MX2020008570A 2018-02-17 2019-02-15 Inhibidores de arginasa y sus metodos de uso. MX2020008570A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631659P 2018-02-17 2018-02-17
US201862671576P 2018-05-15 2018-05-15
US201862721113P 2018-08-22 2018-08-22
US201862778002P 2018-12-11 2018-12-11
PCT/IB2019/051236 WO2019159120A1 (en) 2018-02-17 2019-02-15 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2020008570A true MX2020008570A (es) 2020-09-21

Family

ID=65763693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008570A MX2020008570A (es) 2018-02-17 2019-02-15 Inhibidores de arginasa y sus metodos de uso.

Country Status (22)

Country Link
US (3) US11420984B2 (es)
EP (1) EP3752251A1 (es)
JP (2) JP7317841B2 (es)
KR (1) KR102657919B1 (es)
CN (3) CN117180290A (es)
AU (2) AU2019221896B2 (es)
BR (1) BR112020015973A2 (es)
CA (1) CA3091365A1 (es)
CL (1) CL2020002096A1 (es)
CR (1) CR20200418A (es)
DO (1) DOP2020000145A (es)
EC (1) ECSP20058183A (es)
IL (1) IL276711B2 (es)
JO (1) JOP20200197A1 (es)
MA (1) MA51837A (es)
MX (1) MX2020008570A (es)
NI (1) NI202000055A (es)
PE (1) PE20210176A1 (es)
SG (1) SG11202007739XA (es)
TW (1) TWI803574B (es)
UY (1) UY38096A (es)
WO (1) WO2019159120A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117180290A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
IL303087B1 (en) 2018-02-27 2024-08-01 Incyte Corp Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors
TWI723366B (zh) 2018-03-29 2021-04-01 波蘭商昂科艾倫迪治療法股份公司 二肽哌啶衍生物
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
CN113166153A (zh) 2018-07-05 2021-07-23 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
MX2021002042A (es) * 2018-08-22 2021-04-28 Astrazeneca Ab Inhibidores de arginasa y sus metodos de uso.
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
BR112021015581A2 (pt) * 2019-02-08 2021-10-05 Astrazeneca Ab Inibidores de arginase e seus métodos de uso
CN114599372A (zh) * 2019-11-04 2022-06-07 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348422B (es) * 2010-04-22 2017-06-12 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
SI2632927T1 (sl) 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
US8894970B2 (en) 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
IN2014DN09678A (es) 2012-04-18 2015-07-31 Mars Inc
EP3313410A4 (en) * 2015-06-23 2019-01-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
LT3368541T (lt) 2015-10-30 2020-09-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
SI3559009T1 (sl) 2016-12-22 2021-08-31 Calithera Biosciences, Inc. Sestavki in postopki za zaviranje arginazne dejavnosti
CN111491937A (zh) 2017-12-22 2020-08-04 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的杂环化合物
CN117180290A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
US20210040127A1 (en) 2018-03-13 2021-02-11 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2019205979A1 (zh) 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
EP3810615A4 (en) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE

Also Published As

Publication number Publication date
DOP2020000145A (es) 2020-09-15
CN111712302A (zh) 2020-09-25
ECSP20058183A (es) 2020-10-30
SG11202007739XA (en) 2020-09-29
EP3752251A1 (en) 2020-12-23
PE20210176A1 (es) 2021-01-29
CN111712302B (zh) 2023-09-19
BR112020015973A2 (pt) 2020-12-15
JP7317841B2 (ja) 2023-07-31
KR20200122341A (ko) 2020-10-27
CN117180290A (zh) 2023-12-08
TW201945004A (zh) 2019-12-01
US11420984B2 (en) 2022-08-23
CL2020002096A1 (es) 2020-12-18
JOP20200197A1 (ar) 2020-08-16
US20230365599A1 (en) 2023-11-16
US20230122859A1 (en) 2023-04-20
AU2022203938B2 (en) 2024-02-01
NZ767738A (en) 2023-12-22
CN117186134A (zh) 2023-12-08
IL276711A (en) 2020-09-30
MA51837A (fr) 2021-06-16
IL276711B1 (en) 2024-02-01
IL276711B2 (en) 2024-06-01
NI202000055A (es) 2021-06-22
AU2022203938A1 (en) 2022-06-23
WO2019159120A1 (en) 2019-08-22
US11912727B2 (en) 2024-02-27
KR102657919B1 (ko) 2024-04-15
US20210002305A1 (en) 2021-01-07
CR20200418A (es) 2020-10-27
TWI803574B (zh) 2023-06-01
UY38096A (es) 2019-07-31
AU2019221896A1 (en) 2020-10-01
CA3091365A1 (en) 2019-08-22
JP2023145557A (ja) 2023-10-11
AU2019221896B2 (en) 2022-03-24
JP2021513964A (ja) 2021-06-03

Similar Documents

Publication Publication Date Title
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
JP2013531029A5 (es)
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
CA2668997A1 (en) 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
EA200701780A1 (ru) Противоопухолевое средство
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
RU2019142472A (ru) Глюкуронидные пролекарства ингибиторов янус-киназы
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
GEP20237476B (en) N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
RU2013136895A (ru) Новое бициклическое соединение или его соль
WO2009060282A3 (en) Stilbene derivatives as pstat3/il-6 inhibitors
WO2009047615A3 (en) Novel histone deacetylase inhibitors
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
WO2008087514A3 (en) Hdac inhibitors
WO2009009531A3 (en) Pyrimidinecarboxamide derivatives for the treatment of hiv infections
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.